天宇股份：非沙坦类原料药是核心增长动力，2026年有望继续保持快速增长

Core Viewpoint - Tianyu Co., Ltd. identifies non-sartan active pharmaceutical ingredients (APIs) such as sitagliptin and ezetimibe as core growth drivers, with expectations for continued rapid growth through 2026 and potential for further gross margin improvement due to economies of scale [1] Group 1 - Non-sartan APIs are expected to be a significant growth driver for the company [1] - The company anticipates maintaining rapid growth in the non-sartan API segment through 2026 [1] - There is potential for further improvement in gross margins as economies of scale become more pronounced [1]